Africa CDC warns of regional Ebola spread risk as DRC and Uganda confirm outbreaks

Africa CDC activates continental coordination measures; consultations underway on possible Public Health Emergency declaration

Middle East conflict pushes health systems to brink as casualties, displacement surge: WHO

The conflict is also triggering a widening public health emergency

India’s silent oral cancer crisis: Early detection could save thousands

Presence of Mpox virus of West African clade 2 confirmed in isolated patient

This case is an isolated case, similar to the earlier 30 cases reported in India from July 2022 onwards

Roche responds to WHO’s declaration of health emergency due to mpox outbreak

Roche confirms that its cobas MPXV test, as well as the LightMix research use only kits, detect the latest mpox virus variants

Health Minister Nadda reviews Monkeypox situation and preparedness

Monkeypox infections are usually self-limiting lasting between 2-4 weeks and patients generally recover with supportive management

BioNTech and CEPI partnership to advance mRNA Mpox Vaccine development

The partnership is part of BioNTech’s strategy to develop novel prophylactic vaccines for the prevention of high-medical-need infectious diseases

NIH and Exothera partner to produce GMP intranasal vaccine against SARS-CoV-2 for clinical phase I/II trial in Africa and US

NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials

Seven manufacturers sign sublicence agreements with the MPP to produce generic versions of Shionogi's COVID-19 oral antiviral ensitrelvir

Ensitrelvir is an oral antiviral that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.

Shionogi and MPP sign licence agreement for COVID-19 oral antiviral treatment

Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.